RU2015145134A - Местное лечение воспалительных офтальмологических заболеваний - Google Patents
Местное лечение воспалительных офтальмологических заболеваний Download PDFInfo
- Publication number
- RU2015145134A RU2015145134A RU2015145134A RU2015145134A RU2015145134A RU 2015145134 A RU2015145134 A RU 2015145134A RU 2015145134 A RU2015145134 A RU 2015145134A RU 2015145134 A RU2015145134 A RU 2015145134A RU 2015145134 A RU2015145134 A RU 2015145134A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- alkyl
- use according
- cycle
- form part
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 13
- 230000002757 inflammatory effect Effects 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 206010038886 Retinal oedema Diseases 0.000 claims 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 5
- 206010013774 Dry eye Diseases 0.000 claims 5
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims 5
- 229960000210 nalidixic acid Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- -1 O-alkyl Chemical group 0.000 claims 3
- 201000010183 Papilledema Diseases 0.000 claims 3
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 201000011195 retinal edema Diseases 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 208000031471 Macular fibrosis Diseases 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 102000004550 Angiostatic Proteins Human genes 0.000 claims 1
- 108010017551 Angiostatic Proteins Proteins 0.000 claims 1
- 102000012936 Angiostatins Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010755 Conjunctivitis viral Diseases 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000000964 angiostatic effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960004958 ketotifen Drugs 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229960001810 meprednisone Drugs 0.000 claims 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 1
- 229960005332 zileuton Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1306413.4 | 2013-04-09 | ||
| GB201306413A GB201306413D0 (en) | 2013-04-09 | 2013-04-09 | The local treatment of ophthalmic diseases |
| GB1306411.8 | 2013-04-09 | ||
| GB201306411A GB201306411D0 (en) | 2013-04-09 | 2013-04-09 | Treatment of inflammatory conditions |
| PCT/GB2014/051108 WO2014167326A1 (en) | 2013-04-09 | 2014-04-09 | The local treatment of inflammatory ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015145134A true RU2015145134A (ru) | 2017-05-16 |
| RU2015145134A3 RU2015145134A3 (enExample) | 2018-03-16 |
Family
ID=50489339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015145134A RU2015145134A (ru) | 2013-04-09 | 2014-04-09 | Местное лечение воспалительных офтальмологических заболеваний |
| RU2015145135A RU2015145135A (ru) | 2013-04-09 | 2014-04-09 | Лечение воспалительных расстройств |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015145135A RU2015145135A (ru) | 2013-04-09 | 2014-04-09 | Лечение воспалительных расстройств |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160051526A1 (enExample) |
| EP (2) | EP2983713A1 (enExample) |
| JP (2) | JP2016516761A (enExample) |
| CN (2) | CN105431172A (enExample) |
| AU (2) | AU2014252807A1 (enExample) |
| CA (2) | CA2909117A1 (enExample) |
| GB (2) | GB2516137B (enExample) |
| HK (2) | HK1221190A1 (enExample) |
| RU (2) | RU2015145134A (enExample) |
| WO (2) | WO2014167327A1 (enExample) |
| ZA (2) | ZA201507718B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104496986A (zh) * | 2014-12-12 | 2015-04-08 | 苏州亚科化学试剂股份有限公司 | 萘啶酸的制备方法 |
| CN108348516B (zh) * | 2015-10-29 | 2021-02-12 | 特一华制药株式会社 | 外用剂 |
| AU2017336765B2 (en) | 2016-09-28 | 2023-06-08 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| WO2020021035A1 (en) * | 2018-07-26 | 2020-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of antibiotics for the treatment of immunoglobulin a nephropathy |
| EP3921309A1 (en) * | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same |
| WO2021050649A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19633480A1 (de) * | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
| ID23053A (id) * | 1997-06-04 | 2000-01-20 | Lilly Co Eli | Karboksamida yang digunakan sebagai agonis 5-ht <if> |
| DE19729879C2 (de) * | 1997-07-11 | 1999-07-08 | Mann Gerhard Chem Pharm Fab | Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin |
| DE19826050A1 (de) * | 1998-06-12 | 1999-12-16 | Bayer Ag | Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester |
| CN1090959C (zh) * | 1999-06-17 | 2002-09-18 | 卢世全 | 一种治疗咳喘病的中、西复方成药及制备方法 |
| US6552020B1 (en) * | 1999-07-30 | 2003-04-22 | Allergan, Inc. | Compositions including antibiotics and methods for using same |
| JP2001342188A (ja) * | 2000-03-27 | 2001-12-11 | Takeda Chem Ind Ltd | 縮合ピラゾール誘導体、その製造法および用途 |
| JP3648132B2 (ja) * | 2000-06-19 | 2005-05-18 | 大正薬品工業株式会社 | キノロン系抗菌薬液体製剤及びその包装体 |
| WO2003004098A1 (en) * | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
| RU2424792C2 (ru) * | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| PL2489659T3 (pl) * | 2004-06-24 | 2018-06-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą atp |
| JP2006028031A (ja) * | 2004-07-12 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | 経粘膜吸収用薬物封入ナノ粒子 |
| WO2006039336A2 (en) * | 2004-10-01 | 2006-04-13 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| JP2009518312A (ja) * | 2005-12-02 | 2009-05-07 | ヘルス エンハンスメント プロダクツ インク | 疾患を治療するための植物浸出物の組成物および使用 |
| US20080138350A1 (en) * | 2006-10-20 | 2008-06-12 | Bennett Michael D | Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery |
| CN101129386A (zh) * | 2007-07-17 | 2008-02-27 | 长治市三宝生化药业有限公司 | 一种含环丙沙星和地塞米松的局部悬浮滴眼剂 |
| WO2009037855A1 (ja) * | 2007-09-21 | 2009-03-26 | Nihon Kodoiryo Kenkyukai Co., Ltd. | 口腔用及び皮膚用組成物 |
| GB0719518D0 (en) * | 2007-10-05 | 2007-11-14 | Therapeutics Ltd E | Therapy |
| CA2711957C (en) * | 2007-10-11 | 2019-03-19 | The Regents Of The University Of California | Use of inhibitors of n-acylethanolamine-hydrolyzing acid amidase as anti-inflamatory medicaments |
| MX342183B (es) * | 2008-09-09 | 2016-09-20 | Allergan Inc | Suspension oftalmica para uso ocular. |
| CA2739893C (en) * | 2008-10-07 | 2016-10-04 | Mpex Pharmaceuticals, Inc. | Inhalation of levofloxacin for reducing lung inflammation |
| EP2467138A4 (en) * | 2009-08-19 | 2013-11-06 | Mpex Pharmaceuticals Inc | USE OF AEROSOLIZED ANTIBIOTICS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE |
| EP2515907A1 (en) * | 2009-12-22 | 2012-10-31 | Deutsches Krebsforschungszentrum | Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases |
| MX346312B (es) * | 2011-04-05 | 2017-03-15 | Optosolve Res & Dev Ltd | Tratamientos oftalmicos. |
-
2014
- 2014-04-09 WO PCT/GB2014/051109 patent/WO2014167327A1/en not_active Ceased
- 2014-04-09 CA CA2909117A patent/CA2909117A1/en not_active Abandoned
- 2014-04-09 WO PCT/GB2014/051108 patent/WO2014167326A1/en not_active Ceased
- 2014-04-09 RU RU2015145134A patent/RU2015145134A/ru not_active Application Discontinuation
- 2014-04-09 AU AU2014252807A patent/AU2014252807A1/en not_active Abandoned
- 2014-04-09 US US14/783,038 patent/US20160051526A1/en not_active Abandoned
- 2014-04-09 CA CA2909111A patent/CA2909111A1/en not_active Abandoned
- 2014-04-09 GB GB1406390.3A patent/GB2516137B/en active Active
- 2014-04-09 CN CN201480030407.7A patent/CN105431172A/zh active Pending
- 2014-04-09 US US14/782,975 patent/US20160068527A1/en not_active Abandoned
- 2014-04-09 CN CN201480030418.5A patent/CN105555364A/zh active Pending
- 2014-04-09 EP EP14717821.4A patent/EP2983713A1/en not_active Withdrawn
- 2014-04-09 RU RU2015145135A patent/RU2015145135A/ru not_active Application Discontinuation
- 2014-04-09 HK HK16109376.7A patent/HK1221190A1/zh unknown
- 2014-04-09 HK HK16109377.6A patent/HK1221166A1/zh unknown
- 2014-04-09 JP JP2016507058A patent/JP2016516761A/ja active Pending
- 2014-04-09 JP JP2016507059A patent/JP2016516762A/ja active Pending
- 2014-04-09 GB GB1406396.0A patent/GB2516138C/en active Active
- 2014-04-09 EP EP14717820.6A patent/EP2983788A1/en not_active Withdrawn
- 2014-04-09 AU AU2014252808A patent/AU2014252808A1/en not_active Abandoned
-
2015
- 2015-10-15 ZA ZA201507718A patent/ZA201507718B/en unknown
- 2015-10-15 ZA ZA2015/07724A patent/ZA201507724B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015145134A3 (enExample) | 2018-03-16 |
| GB2516138A (en) | 2015-01-14 |
| HK1221166A1 (zh) | 2017-05-26 |
| GB201406390D0 (en) | 2014-05-21 |
| RU2015145135A (ru) | 2017-05-12 |
| WO2014167327A1 (en) | 2014-10-16 |
| CA2909111A1 (en) | 2014-10-16 |
| US20160051526A1 (en) | 2016-02-25 |
| JP2016516762A (ja) | 2016-06-09 |
| ZA201507724B (en) | 2019-02-27 |
| CN105555364A (zh) | 2016-05-04 |
| CA2909117A1 (en) | 2014-10-16 |
| GB2516138B (en) | 2015-11-25 |
| HK1221190A1 (zh) | 2017-05-26 |
| EP2983713A1 (en) | 2016-02-17 |
| JP2016516761A (ja) | 2016-06-09 |
| EP2983788A1 (en) | 2016-02-17 |
| US20160068527A1 (en) | 2016-03-10 |
| AU2014252808A1 (en) | 2015-11-12 |
| CN105431172A (zh) | 2016-03-23 |
| GB2516138C (en) | 2015-12-09 |
| ZA201507718B (en) | 2019-11-27 |
| GB2516137A (en) | 2015-01-14 |
| WO2014167326A1 (en) | 2014-10-16 |
| GB2516137B (en) | 2016-02-17 |
| GB201406396D0 (en) | 2014-05-21 |
| AU2014252807A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015145134A (ru) | Местное лечение воспалительных офтальмологических заболеваний | |
| JP5583146B2 (ja) | レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物 | |
| JP2009521493A (ja) | 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤 | |
| Schopf et al. | Topical ocular drug delivery to the back of the eye by mucus-penetrating particles | |
| JP2010536797A5 (enExample) | ||
| JP2017514917A (ja) | 眼の疾患および障害を処置するための化合物 | |
| JP2017514917A5 (enExample) | ||
| JP2015528454A5 (enExample) | ||
| JP2006512318A5 (enExample) | ||
| JP2016516761A5 (enExample) | ||
| WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| Xin et al. | Ophthalmic drops with nanoparticles derived from a natural product for treating age-related macular degeneration | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| WO2012105610A1 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
| JP2019524679A5 (enExample) | ||
| JP2010534201A (ja) | 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤 | |
| Sarkar et al. | Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies | |
| Tkachenko et al. | The experience of “Hyloparin” use in clinical practice | |
| WO2017139336A1 (en) | Method of preventing and treating retinal microvasculature inflammation using c-met signaling pathway inhibition | |
| JP2021138710A5 (enExample) | ||
| JP2016520617A5 (enExample) | ||
| JP2013523892A (ja) | 視覚障害を処置するための組成物および方法 | |
| US20250387410A1 (en) | Treatment of anti-vegf refractory ophthalmic retinal eye conditions | |
| CN104703606B (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐在药物组合物中作为视神经网膜保护物使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190429 |